AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31558161 — intervention group
Group type: EXPERIMENTAL
Intervention: Subscale of 'Physical Environment'
Number of subjects: 155
Study 31558161 — intervention group
Group type: COMPARATOR
Intervention: Demographic variables (sex, age, academic degree, working experience)
Number of subjects: 155
Study 27863320 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood adversity (specifically physical abuse)
Number of subjects: 105
Study 27863320 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood adversity (specifically emotional neglect)
Number of subjects: 105
Study 27863320 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood adversity
Number of subjects: 105
Study 26124508 — intervention group
Group type: COMPARATOR
Intervention: Standard quitline treatment
Number of subjects: 1785
Study 26124508 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard plus technology enhanced quitline with 10 risk assessments (TEQ-10)
Number of subjects: 1785
Study 26124508 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard plus 20 TEQ assessments (TEQ-20)
Number of subjects: 1785
Study 24073645 — intervention group
Group type: EXPERIMENTAL
Intervention: Norditropin FlexPro (FP) pen
Number of subjects: 64
Study 24073645 — intervention group
Group type: EXPERIMENTAL
Intervention: Norditropin NordiFlex (NF) pen
Number of subjects: 64
Study 24073645 — intervention group
Group type: COMPARATOR
Intervention: Genotropin GoQuick (GQ) pen
Number of subjects: 64
Study 21782218 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed polyglyconate suture
Number of subjects: 64
Study 21782218 — intervention group
Group type: COMPARATOR
Intervention: Monofilament poliglecaprone suture
Number of subjects: 64
Study 19519885 — intervention group
Group type: COMPARATOR
Intervention: MAMS methodology
Number of subjects: 0
Study 19519885 — intervention group
Group type: COMPARATOR
Intervention: MAMS design
Number of subjects: 0
Study 17186000 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 60 mg p.o. co-administered with morphine
Number of subjects: 12
Study 17186000 — intervention group
Group type: COMPARATOR
Intervention: Placebo co-administered with morphine
Number of subjects: 12
Study 15347373 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg) plus montelukast (10 mg)
Number of subjects: 81
Study 15347373 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg) plus placebo
Number of subjects: 81
Study 15347373 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 81
Study 15347373 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg)
Number of subjects: 81
Study 11133873 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM removal (ILM-off group)
Number of subjects: 48
Study 11133873 — intervention group
Group type: COMPARATOR
Intervention: No ILM removal (ILM-on group)
Number of subjects: 48
Study 9772141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked egg protein (25 g of cooked 13C- and 15N-labeled egg protein)
Number of subjects: 5
Study 9772141 — intervention group
Group type: COMPARATOR
Intervention: Raw egg protein (25 g of raw egg protein)
Number of subjects: 5
Study 7839722 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 1838
Study 7839722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1838
Study 2485986 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 100
Study 2485986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2485986 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy with placebo
Number of subjects: 100
Study 1351 — intervention group
Group type: EXPERIMENTAL
Intervention: Visken (beta-receptor blocking agent)
Number of subjects: 0
Study 1351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31916011 — intervention group
Group type: EXPERIMENTAL
Intervention: One-handed ventilation with an endoscopic bite block
Number of subjects: 59
Study 31916011 — intervention group
Group type: COMPARATOR
Intervention: One-handed ventilation
Number of subjects: 59
Study 31916011 — intervention group
Group type: COMPARATOR
Intervention: Two-handed ventilation
Number of subjects: 59
Study 31916011 — intervention group
Group type: COMPARATOR
Intervention: All ventilation techniques
Number of subjects: 59
Study 30887965 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% ethanolic extract of propolis
Number of subjects: 96
Study 30887965 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% ethanolic extract of propolis
Number of subjects: 96
Study 30887965 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond Universal dentin bonding agent
Number of subjects: 96
Study 30887965 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 96
Study 28166725 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention including practice-based case management, self-management of OAT, and additional patient and practice team education
Number of subjects: 736
Study 28166725 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 736
Study 25062713 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg/day)
Number of subjects: 104
Study 25062713 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 104
Study 23644851 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.2% hypertonic saline - 6% hydroxyethyl starch (HS-HES) solution
Number of subjects: 40
Study 23644851 — intervention group
Group type: COMPARATOR
Intervention: 6% hydroxyethyl starch (HES) solution
Number of subjects: 40
Study 21144516 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian drilling (LOD)
Number of subjects: 26
Study 21144516 — intervention group
Group type: COMPARATOR
Intervention: Control group (fertile regularly menstruating women)
Number of subjects: 26
Study 19934563 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF) for 30 sessions (45 minutes each) at a frequency of 1 Hz and current intensity of 30 mili ampere.
Number of subjects: 12
Study 19934563 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment for 30 sessions (45 minutes each).
Number of subjects: 12
Study 19934563 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF)
Number of subjects: 12
Study 19934563 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 12
Study 17032714 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 0.1 IU/kg per day
Number of subjects: 61
Study 17032714 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 0.2 IU/kg per day
Number of subjects: 61
Study 17032714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 15486358 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT) - treadmill and cycle exercise, n = 9
Number of subjects: 18
Study 15486358 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Strength Training (COMT) - treadmill and cycle exercise plus upper- and lower-extremity strength training, n = 9
Number of subjects: 18
Study 11482341 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2x 1 g daily
Number of subjects: 56
Study 11482341 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A (CsA) aiming at blood trough levels of 120-150 ng/ml
Number of subjects: 56
Study 11482341 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 56
Study 11482341 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A (CsA)
Number of subjects: 56
Study 9591815 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel
Number of subjects: 348
Study 9591815 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.05% gel
Number of subjects: 348
Study 9591815 — intervention group
Group type: COMPARATOR
Intervention: Fluocinonide 0.05% cream
Number of subjects: 348
Study 7820892 — intervention group
Group type: EXPERIMENTAL
Intervention: Econazole
Number of subjects: 102
Study 7820892 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole
Number of subjects: 102
Study 3236268 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilation suggestion
Number of subjects: 30
Study 3236268 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoconstriction suggestion
Number of subjects: 30
Study 3236268 — intervention group
Group type: COMPARATOR
Intervention: Neutral suggestion
Number of subjects: 30
Study 31087132 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy including glucocorticoids and methotrexate
Number of subjects: 0
Study 31087132 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractory JDM treatments including azathioprine, ciclosporin, intravenous immune globulins, mycophenolate mofetil, and rituximab
Number of subjects: 0
Study 31087132 — intervention group
Group type: EXPERIMENTAL
Intervention: Validated tools for assessing disease activity, disease damage, and treatment responses
Number of subjects: 0
Study 30018221 — intervention group
Group type: EXPERIMENTAL
Intervention: School nutrition intervention (classroom-based education sessions and provision of locally-prepared healthy snacks)
Number of subjects: 296
Study 30018221 — intervention group
Group type: EXPERIMENTAL
Intervention: School nutrition intervention
Number of subjects: 296
Study 30018221 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 296
Study 26490677 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted five-cut CT scan protocol with low radiation exposure (0.002 mSv)
Number of subjects: 36
Study 26490677 — intervention group
Group type: EXPERIMENTAL
Intervention: AOFAS scores obtained at a minimum of 1 year after surgery
Number of subjects: 36
Study 26490677 — intervention group
Group type: COMPARATOR
Intervention: Contralateral ankle used as control
Number of subjects: 36
Study 23790592 — intervention group
Group type: EXPERIMENTAL
Intervention: MIG welding of aluminium
Number of subjects: 12
Study 23790592 — intervention group
Group type: EXPERIMENTAL
Intervention: MIG soldering of zinc coated materials
Number of subjects: 12
Study 23790592 — intervention group
Group type: COMPARATOR
Intervention: Filtered ambient air
Number of subjects: 12
Study 22653043 — intervention group
Group type: EXPERIMENTAL
Intervention: RenalGuard therapy (hydration with saline and NAC controlled by the RenalGuard System and furosemide)
Number of subjects: 292
Study 22653043 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate solution and N‐acetylcysteine (NAC) (Control group)
Number of subjects: 292
Study 22653043 — intervention group
Group type: EXPERIMENTAL
Intervention: RenalGuard therapy
Number of subjects: 292
Study 22653043 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 292
Study 19887054 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 30
Study 19887054 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensive healthy persons)
Number of subjects: 30
Study 17261422 — intervention group
Group type: EXPERIMENTAL
Intervention: Target hemoglobin level of 13 to 15 g/dL (group 1)
Number of subjects: 172
Study 17261422 — intervention group
Group type: COMPARATOR
Intervention: Target hemoglobin level of 10.5 to 11.5 g/dL (group 2)
Number of subjects: 172
Study 15297194 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin and radiotherapy (RT)
Number of subjects: 494
Study 11260007 — intervention group
Group type: EXPERIMENTAL
Intervention: SDZ ASM 981 1% cream
Number of subjects: 16
Study 11260007 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone‐17‐valerate 0.1% cream
Number of subjects: 16
Study 11260007 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide 0.1% cream
Number of subjects: 16
Study 11260007 — intervention group
Group type: COMPARATOR
Intervention: Vehicle of SDZ ASM 981 1% cream
Number of subjects: 16
Study 9558039 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐Methylpyrazole (4‐MP), 15 mg/kg body weight dissolved in 50 ml of orange juice
Number of subjects: 14
Study 9558039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9558039 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐Methylpyrazole (4‐MP)
Number of subjects: 14
Study 7520209 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue-type plasminogen activator (t-PA)
Number of subjects: 103
Study 7520209 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 103
Study 7520209 — intervention group
Group type: EXPERIMENTAL
Intervention: ST depression
Number of subjects: 103
Study 7520209 — intervention group
Group type: EXPERIMENTAL
Intervention: No ST depression
Number of subjects: 103
Study 7520209 — intervention group
Group type: EXPERIMENTAL
Intervention: ejection fraction
Number of subjects: 103
Study 3243929 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine (12.5 mg) administered after fasting
Number of subjects: 12
Study 3243929 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine (12.5 mg) administered after a standardized breakfast
Number of subjects: 12
Study 31008744 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-containing hydrofiber dressings
Number of subjects: 60
Study 28361616 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment plus standard medical therapy
Number of subjects: 344
Study 28361616 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy alone
Number of subjects: 344
Study 25933031 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg
Number of subjects: 25
Study 25933031 — intervention group
Group type: COMPARATOR
Intervention: Alendronate 70 mg weekly
Number of subjects: 25
Study 23579816 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy
Number of subjects: 0
Study 23579816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21336108 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (1 mg over 30 mins followed by continuous infusion of 2 μg·kg(‐1)·h(‐1) for 48 hrs)
Number of subjects: 30
Study 21336108 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 30
Study 19858438 — intervention group
Group type: EXPERIMENTAL
Intervention: High social support treatment
Number of subjects: 193
Study 19858438 — intervention group
Group type: COMPARATOR
Intervention: Low social support treatment
Number of subjects: 193
Study 19858438 — intervention group
Group type: EXPERIMENTAL
Intervention: Family index participants
Number of subjects: 193
Study 19858438 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual index participants
Number of subjects: 193
Study 19858438 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intention-to-treat
Number of subjects: 193
Study 19858438 — intervention group
Group type: EXPERIMENTAL
Intervention: High support group with partners attending more counseling sessions
Number of subjects: 193
Study 19858438 — intervention group
Group type: EXPERIMENTAL
Intervention: Low support group with partners attending more counseling sessions
Number of subjects: 193
Study 19858438 — intervention group
Group type: EXPERIMENTAL
Intervention: High support group with partners losing at least 5% of baseline weight
Number of subjects: 193
Study 19858438 — intervention group
Group type: EXPERIMENTAL
Intervention: Low support group with partners losing at least 5% of baseline weight
Number of subjects: 193
Study 17805438 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine
Number of subjects: 68
Study 17805438 — intervention group
Group type: COMPARATOR
Intervention: 0.25% ropivacaine
Number of subjects: 68
Study 15450119 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mcg vaginal misoprostol
Number of subjects: 163
Study 15450119 — intervention group
Group type: COMPARATOR
Intervention: 3 mg dinoprostone
Number of subjects: 163
Study 10931388 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional immunotherapy (IT)
Number of subjects: 10
Study 10931388 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid (TT) stimulation
Number of subjects: 10
Study 10931388 — intervention group
Group type: COMPARATOR
Intervention: Allergic control patients (AC group)
Number of subjects: 10
Study 9065532 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD subjects
Number of subjects: 30
Study 8218956 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovator product (Negram‐Winthrop‐Breon)
Number of subjects: 12
Study 8218956 — intervention group
Group type: COMPARATOR
Intervention: Two products with lower bioavailability
Number of subjects: 12
Study 2947106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract
Number of subjects: 166
Study 2947106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 31574585 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation intervention (RELAX; face‐to‐face classes and daily home practice of progressive muscle relaxation and mindfulness meditation)
Number of subjects: 36
Study 31574585 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (CON)
Number of subjects: 36
Study 29588187 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine baths
Number of subjects: 0
Study 29588187 — intervention group
Group type: COMPARATOR
Intervention: Control (before implementation of chlorhexidine baths)
Number of subjects: 0
Study 27320058 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (52.6%, n = 49)
Number of subjects: 93
Study 27320058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (44.1%, n = 41)
Number of subjects: 93
Study 27320058 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaptanib (7.5%, n = 7)
Number of subjects: 93
Study 27320058 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (5.4%, n = 5)
Number of subjects: 93
Study 24315218 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational enhancement intervention (up to 5 sessions lasting 10-30 minutes each)
Number of subjects: 330
Study 24315218 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 330
Study 23598289 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 5 U
Number of subjects: 76
Study 23598289 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin 100 μg
Number of subjects: 76
Study 23598289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 20675978 — intervention group
Group type: EXPERIMENTAL
Intervention: CER 15 mg
Number of subjects: 504
Study 20675978 — intervention group
Group type: EXPERIMENTAL
Intervention: CER 30 mg
Number of subjects: 504
Study 20675978 — intervention group
Group type: COMPARATOR
Intervention: CIR 10 mg
Number of subjects: 504
Study 20675978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 504
Study 17405870 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 40
Study 17405870 — intervention group
Group type: COMPARATOR
Intervention: Assisted-control ventilation plus volume guarantee (VG) (Vt = 5 ml/kg)
Number of subjects: 40
Study 16292641 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate combined with ketamine (10 mM)
Number of subjects: 18
Study 16292641 — intervention group
Group type: COMPARATOR
Intervention: Glutamate (1 M, 0.2 ml) alone
Number of subjects: 18
Study 14574094 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-session intervention
Number of subjects: 152
Study 14574094 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-session intervention
Number of subjects: 152
Study 14574094 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 152
Study 11387282 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic salpingectomy
Number of subjects: 26
Study 11387282 — intervention group
Group type: COMPARATOR
Intervention: No surgical intervention
Number of subjects: 26
Study 9365148 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg preprandial
Number of subjects: 16
Study 9365148 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg postprandial
Number of subjects: 16
Study 9365148 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg postprandial
Number of subjects: 16
Study 9365148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8466733 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release isradipine (SRO) 2.5 mg
Number of subjects: 190
Study 8466733 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release isradipine (SRO) 5 mg
Number of subjects: 190
Study 8466733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 3959323 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 liter of 3% amino acid solution daily for 5 days postoperatively
Number of subjects: 22
Study 3959323 — intervention group
Group type: COMPARATOR
Intervention: Balanced 5% glucose-containing electrolyte solutions
Number of subjects: 22
Study 29882884 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (LCD)
Number of subjects: 56
Study 29882884 — intervention group
Group type: COMPARATOR
Intervention: Low-Fat Diet (LFD)
Number of subjects: 56
Study 27289472 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily (bid)
Number of subjects: 85
Study 27289472 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg bid
Number of subjects: 85
Study 27289472 — intervention group
Group type: COMPARATOR
Intervention: Comparison of IPA between ranitidine and omeprazole groups after excluding homozygous patients for 2C19*2 genotype
Number of subjects: 85
Study 24375313 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal Function Exercises (VFE)
Number of subjects: 16
Study 24375313 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonation Resistance Training Exercise (PhoRTE)
Number of subjects: 16
Study 24375313 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group (CTL)
Number of subjects: 16
Study 22210078 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless amniotic membrane patch with a modified symblepharon ring
Number of subjects: 75
Study 22210078 — intervention group
Group type: COMPARATOR
Intervention: Conventional sutured amniotic membrane patch
Number of subjects: 75
Study 20537750 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 25/75 (LM25)
Number of subjects: 580
Study 20537750 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 580